Phosphorylation of ERK1/2 in Patients With Parkinson’s Disease

Overview

Levodopa-induced dyskinesia severely limits the use of levodopa in Parkinson's disease and constitutes a debilitating complication of dopaminergic treatment in late stage. Among several neurobiological mechanisms identified so far, the investigators have established in experimental models the key role of D1 receptor hypersensitivity and a"Ras-ERK" signalling pathway. As the very same dopamine receptor machinery and the Ras-ERK pathway are present in blood lymphocytes, the investigators wish to test the hypothesis that the level of ERK phosphorylation in lymphocytes is a biomarker of levodopa-induced dyskinesia in Parkinson's Disease. The study will be performed in dyskinetic levodopa-treated patients and non-Parkinson's Disease controls. Blood sampling "off" and "on" levodopa treatment (1 hour post-dose), as well as clinical data collection will be done during a scheduled pre-op work-up (deep brain stimulation). Subsequently, suspended lymphocytes from blood samples will be immunolabelled using an anti-pERK antibody and mean fluorescence intensity and percent of labelled lymphocytes will be assessed by flow cytometry. Additionally, plasma and urine samples will be collected "on" et "off" for dosage of dopamine. The motor effect of levodopa will be assessed through UPRSIII rating scale and eye movement (saccades) speed by non-invasive oculometric recordings.

Full Title of Study: “A Descriptive Study of Lymphocytic Phosphorylation of ERK1/2 in Patients With Parkinson’s Disease With Dyskinesias and in Controls”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: July 2012

Interventions

  • Other: Clinical variables
    • Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
  • Other: Clinical variables
    • Demography, Biological variables.
  • Other: Clinical variables
    • Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson’s disease group) levodopa(10 to 15 minute/recording)

Arms, Groups and Cohorts

  • Parkinson’s Disease patient
    • levodopa-treated parkinson’s disease (PD) patients
  • Non Parkinson’s disease controls
    • Non Parkinson’s disease controls

Clinical Trial Outcome Measures

Primary Measures

  • ERK phosphorylation
    • Time Frame: Day 1
    • Distribution of variables and difference in the state of ERK phosphorylation in two contrasted groups : the dyskinetic levodopa-treated PD group and control group.

Secondary Measures

  • plasma and urinary dopamine in “on” and “off” state
    • Time Frame: Day 1
  • measure derivatives of morphine
    • Time Frame: Day 1

Participating in This Clinical Trial

Inclusion Criteria

  • Consecutive eligible PD in- and outpatients selected at the university hospital of Bordeaux. – Non-demented patients (DSM IV) who are able to give their informed consent and who are affiliated to the social security. – Controls: Subjects without known neurological disorder, non-demented, able to give their informed consent and affiliated to the social security. Exclusion Criteria:

  • Patients: Atypical or secondary parkinson disease. – Previous or current cancer or malignant haemopathy. – Known auto-immune disease. – Anti-neoplastic or immuno-modulator treatment (particularly corticosteroids). Immuno-deficient subjects. – Acute viral infection (within 2 weeks after resolving). Statin drug intake. Demented subject (DSMIV). – Controls: Same criteria as above plus any neurological disease.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Bordeaux
  • Collaborator
    • Université Victor Segalen Bordeaux 2
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Nathalie DAMON-PERRIERE, Dr., Principal Investigator, University Hospital, Bordeaux
    • Geneviève CHENE, Pr, Study Chair, University Hospital, Bordeaux

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.